以全基因體shRNA篩選能於YT細胞誘發受T-bet調控的標記之微RNA

Genome-wide shRNA screen in YT cells for induction of T-bet- regulated markers

黃偉庭(Wei-Ting Huang)

指導教授 ： 林中梧

國立臺灣大學/醫學院/病理學研究所/碩士(2014年)

https://doi.org/10.6342/NTU.2014.10600

摘要

Epstein-Barr病毒（EBV）感染常見於淋巴瘤疾病而鼻腔NK細胞淋巴瘤(NNL)是個與EBV病毒相關並由鼻黏膜中的細胞毒性NK細胞與T細胞衍伸而來。EB病毒編碼的miR-BART20-5P抑制T-bet和IFNg並間接抑制p53導致疾病發展的鼻腔NK細胞淋巴瘤（NNL）。
除此之外，我們尚研究EBV病毒如何藉由病毒本身的microRNAs來抑制IFN-γ-STAT1路徑以提升病毒的複製與主流的生長。在EBV−的Jurkat細胞當中，轉染miR-BART20-5p以及miR-BART8各別抑制了luciferase-IFN-γ-3’-UTR和luciferase-STAT1-3’-UTR的轉譯。在EBV+ IFN-γ表現弱/STAT1表現強的YT白血病細胞與IFN-γ表現強/STAT1表現弱的NK92細胞中，miR-BART20-5p與IFN-γ mRNAs或miR-BART8與STAT1 mRNAs在細胞內的相對表現量影響標的基因的表現。染色質免疫沉澱實驗顯示STAT1調節腫瘤抑制基因P53以及miR-let7a的轉錄。此外，使miR-BART8於YT細胞中過度表現或使miR-BART20-5p於NK92細胞中過度表現會抑制p53的表現而造成腫瘤對doxorubicin的抗藥性，這項實驗結果與前述實驗結果相符。於36位NNL的病人當中，miR-BART20-5p或miR-BART8的表現量與STAT1之表現呈現反比結果。除此之外，於46位NNL病人案例中，同時具有miR-BART20-5p和miR-BART8表現的一群NNL病人之p53 mRNAs均有下降情形且伴隨著疾病嚴重進展。因此，我們下了一個結論，EB病毒編碼的miR-BART20-5P和miR-BART8抑制干擾素IFN-γ-STAT1途徑與疾病進展的鼻NK細胞淋巴瘤息息相關 (已發表於2014年的AJP) (Appendix Figure 3)。
核醣核蛋白聚合物(RNPCs)可能調節著T-bet的轉譯過程。為了辨識這些核醣核蛋白聚合物，我們採用全基因體shRNA以分離並辨識那些可能誘導T-bet或是T-bet調節的標記的shRNAs。全基因體shRNAs同時也藉由病毒感染方式送入EBV+ 的YT-20-5p-ECFP-IRES-Tbet-EGFP細胞株，且在此實驗當中，我們以辨識出一些有表現ECFP(藍光)的clones。一些shRNAs已從分離出的clones當中定序出來且正進行進一步的確認實驗。
(關鍵詞：EBV病毒，鼻腔NK細胞淋巴瘤，NK細胞，T-bet，IFN-γ，miR-BART20-5p)

關鍵字

EBV病毒 ； 鼻腔NK細胞淋巴瘤 ； NK細胞 ； T-bet ； IFN-γ ； miR-BART20-5p

並列摘要

Epstein-Barr virus (EBV) infection is frequently found in lymphomas, and Nasal NK/T-cell lymphoma (NNL) is an Epstein-Barr virus (EBV)-associated lymphoma derived from cytotoxic NK or T cells of the nasal mucosa. The EBV-encoded miR-BART20-5p inhibits T-bet and IFN-γ with secondary suppression of p53 and disease progression in nasal NK-cell lymphoma (NNL).
Furthermore, we investigated how EBV may have used miRNAs of viral origin to inhibit the IFN-γ-STAT1 pathway to facilitate viral replication and tumor growth. In EBV− Jurkat cells, transfection of miR-BART20-5p and miR-BART8 inhibited translation of luciferase-IFN-γ-3’-UTR and luciferase-STAT1-3’-UTR, respectively. In EBV+ IFN-γ weak/STAT1 strong YT leukemic cells and IFN-γ strong/STAT1 weak NK92 cells, relative endogenous levels between miR-BART20-5p and IFN-γ mRNAs or between miR-BART8 and STAT1 mRNAs determined expression of the targets. Chromatin immune precipitation studies showed that STAT1 regulates the transcription of the tumor suppressor TP53 (encoding p53) and miR-let7a. Consistent with these findings, overexpression of miR-BART8 in YT cells or of miR-BART20-5p in NK92 cells inhibited p53 and increased resistance to doxorubicin. In 36 NNLs, the levels of miR-BART20-5p or miR-BART8 correlated inversely with the expression of STAT1. Additionally, in 46 NNLs, expression of both miR-BART20-5p and miR-BART8 identified a group of NNLs with decreased p53 mRNAs and evidence of disease progression. We conclude that miR-BART20-5p and miR-BART8 cause progression of nasal NK-cell lymphomas through inhibition of the IFN-g-STAT1 pathway (Am J Path, 2014) (Appendix Figure 3.).
Multiple ribonucleoprotein complexes (RNPCs) might regulate T-bet translation. To identify these RNPCs, we have used genome-wide shRNA library to isolate and identify the shRNAs which can induce T-bet or T-bet-regulated markers. The library was also transduced into EBV+ YT-20-5p-ECFP-IRES-Tbet-EGFP cells, and ECFP positive clones were identified. Several shRNAs have been sequenced in the isolated clones and processed for further confirmation.
(Key words：EBV, Nasal NK/T-cell lymphoma (NNL), NK cell, T-bet, IFN-γ, miR-BART20-5p)

並列關鍵字

EBV ； Nasal NK/T-cell lymphoma (NNL) ； NK cell ； T-bet ； IFN-γ ； miR-BART20-5p

參考文獻

1 Lin, T. C., Chen, S. U., Chen, Y. F., Chang, Y. C. & Lin, C. W. Intramucosal variant of nasal natural killer (NK)/T cell lymphoma has a better survival than does invasive variant: implication on loss of E26 transformation-specific sequence 1 (ETS-1) and T-box expressed in T cells (T-bet) with invasion. Histopathology 60, 287-295, doi:10.1111/j.1365-2559.2011.04086.x (2012).

2 Young, H. A. & Bream, J. H. IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications. Current topics in microbiology and immunology 316, 97-117 (2007).

3 Lanier, L. L. Evolutionary struggles between NK cells and viruses. Nature reviews. Immunology 8, 259-268, doi:10.1038/nri2276 (2008).

4 Reich, N. C. STAT dynamics. Cytokine & growth factor reviews 18, 511-518, doi:10.1016/j.cytogfr.2007.06.021 (2007).

5 Kim, H. S. & Lee, M. S. STAT1 as a key modulator of cell death. Cellular signalling 19, 454-465, doi:10.1016/j.cellsig.2006.09.003 (2007).